The role of bevacizumab in colorectal cancer: understanding its benefits and limitations.
about
Triphala and its active constituent chebulinic acid are natural inhibitors of vascular endothelial growth factor-a mediated angiogenesisThe Mesothelial Origin of Carcinoma Associated-Fibroblasts in Peritoneal MetastasisLower exposure and faster clearance of bevacizumab in gastric cancer and the impact of patient variables: analysis of individual data from AVAGAST phase III trial.Vascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: a prospective phase I subanalysisAngiopreventive efficacy of pure flavonolignans from milk thistle extract against prostate cancer: targeting VEGF-VEGFR signaling.Development, optimization, and validation of novel anti-TEM1/CD248 affinity agent for optical imaging in cancerE7080 (lenvatinib), a multi-targeted tyrosine kinase inhibitor, demonstrates antitumor activities against colorectal cancer xenografts.Simultaneous inhibition of EGFR/VEGFR and cyclooxygenase-2 targets stemness-related pathways in colorectal cancer cellsMonitoring early tumor response to drug therapy with diffuse optical tomography.Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases.Antibody-based therapy in colorectal cancer.Novel drug discovery opportunities for colorectal cancer.Design and evaluation of radiolabeled tracers for tumor imaging.Antibody-based tumor vascular theranostics targeting endosialin/TEM1 in a new mouse tumor vascular model.Tumor vessel stabilization and remodeling by anti-angiogenic therapy with bevacizumab.Procyanidin B2 3,3″-di-O-gallate inhibits endothelial cells growth and motility by targeting VEGFR2 and integrin signaling pathwaysCharacterization of the long-term pharmacokinetics of bevacizumab following last dose in patients with resected stage II and III carcinoma of the colon.Next-generation sequencing analysis of receptor-type tyrosine kinase genes in surgically resected colon cancer: identification of gain-of-function mutations in the RET proto-oncogene.
P2860
Q21090869-8A12C7D2-F831-4496-8E6A-8FA0F424D797Q26783022-8D5FB920-11B6-4796-9DBD-4EA7DDDBC7B8Q30831967-AF558BC3-FFB7-49D6-9E2F-684D399CE393Q33926377-12297AFC-940D-4B8E-9697-6BF0546D5CBBQ34238619-9B5D2865-71E5-401A-B1B1-28B6BED3F1B0Q34334475-CD5CAAEF-8342-43CC-A1CE-E92AE60635D4Q34558883-507EF0A8-56DC-4C6A-AECB-0C6C254C922DQ35673201-FE75DD82-0B91-45B9-990D-DE99AA7066D5Q36051383-ACDC4D70-9CE2-4907-9F80-D5122A6916C7Q36072776-6D274E1A-1D6B-4688-BCAF-EE4FABBD0AC1Q38103583-3E22D3A7-CAD6-4741-845F-442E3AEABE36Q38114502-0C1D055A-A61D-4A8F-B999-800036233CB5Q38137253-F3640D78-D310-4B24-8F6D-94902B785316Q38662532-BD468497-1803-44AD-801D-23925BABF4F5Q39423599-05F47411-B594-4428-92E5-297F4899DC87Q41858794-47FA2A2B-A371-4E97-9745-EFDBB3CF5379Q51289585-F734B663-D41C-4445-86CC-8D8C0B310D1BQ52582448-C7ED3B66-31A9-4472-816C-AEAE69CD4C04
P2860
The role of bevacizumab in colorectal cancer: understanding its benefits and limitations.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The role of bevacizumab in colorectal cancer: understanding its benefits and limitations.
@en
The role of bevacizumab in colorectal cancer: understanding its benefits and limitations.
@nl
type
label
The role of bevacizumab in colorectal cancer: understanding its benefits and limitations.
@en
The role of bevacizumab in colorectal cancer: understanding its benefits and limitations.
@nl
prefLabel
The role of bevacizumab in colorectal cancer: understanding its benefits and limitations.
@en
The role of bevacizumab in colorectal cancer: understanding its benefits and limitations.
@nl
P2093
P2860
P1476
The role of bevacizumab in colorectal cancer: understanding its benefits and limitations.
@en
P2093
Andrew Scarfe
Jennifer Spratlin
Karen Mulder
P2860
P304
P356
10.1517/14712598.2011.557657
P407
P577
2011-02-01T00:00:00Z